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Abstract
Castleman disease is a very rare, lymphoproliferative disease, driven by dysregulation of the cytokine interleukin 6 (IL-6) 
and other proinflammatory cytokines with the development of symptoms of systemic inflammation, reactive proliferation 
of lymphocytes, and damage to numerous organs. HHV-8 infection plays a major role in the pathogenesis of human im-
munodeficiency virus (HIV+) multicentric Castleman disease (MCD). The aetiology of the idiopathic form of MCD (HIV/ 
/HHV-8 negative) is unknown.
In 2017, a panel of Castleman Disease Collaborative Network (CDCN) experts developed unified diagnostic criteria 
necessary for the diagnosis of idiopathic MCD. The disease has a diverse course, with a broad spectrum from mild to 
severe. The drug of choice according to the CDCN recommendation of 2018 for patients requiring treatment is anti-
-IL-6 monoclonal antibody, siltuximab. Immunomodulatory and immunosuppressive drugs are an alternative first-line 
treatment when anti-IL-6/IL-6R drugs are unavailable, and in subsequent lines of treatment after the failure of anti-IL-6 
antibodies. Chemotherapy is reserved for the treatment of severe forms of the disease. The prognosis in most patients 
is moderately good. Unfortunately, the availability of the new therapies remains limited.
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Introduction
Castleman disease (CD) is a very rare, non-neoplastic lymph 
node hyperplasia of unknown aetiology. Excessive release 
of interleukin 6 (IL-6) and other pro-inflammatory cytokines 
results in systemic inflammation, reactive lymphocyte 
proliferation, and organ damage. CD was first described 
by Benjamin Castleman in 1954 as angiofollicular lymph 
node hyperplasia limited to one nodal group, now classi-
fied as unicentric Castleman disease (UCD) [1]. Similar 
lesions involving several nodal groups simultaneously, 
described by Gaba et al. in 1974, usually accompanied by 
systemic symptoms, are now diagnosed as multicentric 
Castleman disease (MCD) [2]. In the 1980s, MCD diagnosis 
was correlated with immune deficiencies, mainly related 
to human immunodeficiency virus (HIV) infection. Since 
then, HIV-associated MCD cases and those unrelated to 
HIV infection (HIV–) have been systematically distinguished 
[3]. MCD has been also associated with POEMS syndrome 
(polyneuropathy, organomegaly, endocrine disorders, 
monoclonal gammopathy and skin lesions). The discovery 
of a direct link between HIV-associated MCD and human 
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herpesvirus 8 (HHV-8/KSHV, Kaposi sarcoma herpesvirus) 
infection was a breakthrough in our understanding of the 
pathogenesis of CD. It has been shown that HHV-8 replicat-
ing in plasmablastic cells in germinal centres stimulates 
the secretion of both viral and human IL-6 and many other 
pro-inflammatory proteins, which leads to characteristic 
histopathological (HP) lesions in the structure of lymph 
nodes [4]. The discovery of the key role of HHV-8 in the 
pathogenesis of HIV-associated MCD and the potential role 
of monoclonal plasma cells in the pathogenesis of POEMS- 
-MCD contributed to the reclassification of CD. The Castle-
man Disease Collaborative Network (CDCN) has proposed 
a classification system distinguishing the disease into 1) CD 
of known or suspected aetiology, i.e. related to HHV-8 in-
fection (HHV8-MCD) often coinciding with HIV infection; 2) 
cases associated with POEMS (POEMS-MCD); and 3) idio-
pathic MCD (iMCD) HHV8(–)/HIV(–) of unknown aetiology 
[5, 6]. First described in 2010 in Japan, TAFRO syndrome 
(thrombocytopenia, ascites, reticulin bone marrow fibrosis, 
renal failure, and organomegaly) has now been recognised 
as a variant of idiopathic MCD, i.e. iMCD-TAFRO [7]. Patients 
who do not meet the diagnostic criteria of TAFRO syndrome 
are classified as having idiopathic multicentric Castleman 
disease, not otherwise specified (iMCD-NOS) [6].
The incidence of Castleman disease in the general 
population is unknown. In the United States, approximate-
ly 4,750 new cases of CD are diagnosed annually, usually 
UCD (80–90%). In multicentric disease, 30–60% of cases 
are idiopathic [6, 8]. The best prognosis is for unicentric 
disease (UCD). In these cases, surgical resection of the le-
sion (the treatment of choice) results in long-term disease-
free survival (DFS) in more than 90% of patients [9]. The 
prognosis of idiopathic MCD depends on the severity of 
clinical symptoms. Before the anti-IL6 antibody era, 5-year 
overall survival (OS) was 55–77% [10]. The introduction of 
anti-IL6/IL-6R therapy has significantly improved the qual-
ity of life of many patients and prolonged overall survival, 
especially in the mild form of MCD. Yet the prognosis in the 
severe disease, including patients with TAFRO syndrome, 
is still unsatisfactory [11, 12]. The treatment of HIV-asso-
ciated MCD patients with a combination of antiretroviral 
therapy and rituximab has been a great success, increas-
ing 5-year OS from 33% to 90% [13].
Pathogenesis of idiopathic multicentric 
Castleman disease
CD is believed to result from the dysregulation of the 
immune system due to the excessive secretion of pro-
inflammatory cytokines. The current pathogenesis model 
assumes that lymph node hyperplasia and characteristic HP 
lesions result from the response to an excess of cytokines, 
mainly IL-6. For several years, the involvement of three main 
cytokine-stimulating mechanisms has been considered: 
1) autoimmune inflammation hypothesis; 2) paraneoplas-
tic syndrome with ectopic cytokine secretion hypothesis; 
and 3) cytokine stimulation by viruses other than HHV-8 
hypothesis [5, 14]. The relationship between CD and infec-
tion with viruses other than HHV-8, including Epstein-Barr 
virus (HHV-4, human herpesvirus 4) and other viruses from 
the Herpesviridae family, has not been confirmed [5, 15].
The hypothesis suggesting an autoimmune background 
highlights the role of germline mutations in immune system 
genes (innate immunity) and the production of abnormal 
antibodies. In the lymph nodes, autoantibodies stimulate 
antigen presenting cells to secrete cytokines [IL-1/tumour 
necrosis factor alpha (TNF-α)], and presumably could ac-
tivate yet unknown (MCD-related) cells to overproduce 
IL-6 and other pro-inflammatory cytokines. In a feedback 
loop, interleukin 6 may stimulate inflammatory cells to ex-
cessive secretion of cytokines (in a kind of vicious circle) [5]. 
Many autoimmune diseases that develop in consequence 
of unclear, complex immune system disorders leading to 
inflammatory response in various tissues and organs, in-
cluding rheumatoid arthritis (RA), Sjögren’s syndrome, 
systemic lupus erythematosus (SLE), and myasthenia gra-
vis, may coexist with similar histopathological features of 
lymph nodes as in CD.
According to the currently accepted criteria, several in-
flammatory and autoimmune diseases have to be excluded 
in order to diagnose iMCD. Importantly, the presence of an-
tibodies can result from MCD activity only. In approximately 
30% of iMCD cases, anti-nuclear antibodies (ANA), anti- 
-Sjögren-syndrome-related antigen A antibodies (SS-A), anti- 
-platelet or anti-erythrocyte antibodies may be present with-
out the diagnosis of another autoimmune disease [6, 16].
An alternative hypothesis suggests that CD is a paraneo-
plastic syndrome. Somatic mutations lead to the formation 
of a small pool of monoclonal stromal cells secreting pro-
inflammatory cytokines in the lymph nodes, which become 
a ‘trigger mechanism’ that drives cytokine production fur-
ther. Next Generation Sequencing studies have shown that 
platelet-derived growth factor beta (PDGFRβ) mutations are 
present in lymph nodes in nearly 20% of patients with UCD, 
and the mutations are probably present in the stromal cells 
(CD45-negative cells) [17]. Analogically to the paraneoplas-
tic POEMS syndrome, in which monoclonal plasmocytes con-
stituting only a small percentage of bone marrow cells are 
responsible for the excessive secretion of vascular endo-
thelial growth factor (VEGF) and, consequently, to systemic 
disorders, it has also been shown that patients diagnosed 
with CD have a higher risk of cancer compared to the gen-
eral population of a similar age (19% vs. 6%) [5, 16].
To explain the mechanisms underlying the pathogen-
esis of MCD, whole-exome sequencing (WES) studies have 
been performed, which allowed the selection of five unfa-
vourable prognostic genes. Among these, NCOA4 (nuclear 
receptor coactivator 4), also known as ARA70 (androgen 
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receptor-associated protein 70), encoding nuclear recep-
tor coactivator 4 protein (NCOA4), is of particular interest.
Abnormal expression and function of NCOA4 has been 
associated with carcinogenesis. L261F mutation in the 
NCOA4 gene appears to be highly specific for the idiopathic 
form of MCD. NCOA4 dysfunction may play an important role 
in the pathogenesis of CD through its association with MAP 
kinase (mitogen-activated protein kinase), which controls 
one of the most important pathways activating IL-6 [18]. 
Recent studies have suggested that excessive activation of 
T cells and mTOR protein kinase (mammalian target of ra-
pamycin), associated with the intracellular PI3K/AKT/mTOR 
signalling pathway, may play a key role in the pathogenesis 
of iMCD. Early attempts to use mTOR inhibitors in the ther-
apy are promising, and a study with sirolimus is underway 
in patients resistant to anti-IL6 antibodies [19].
Cytokines and their role in the pathogenesis 
of Castleman disease
A key role in the development of CD is attributed to IL-6, 
a multifunctional cytokine secreted by lymphocytes, macro-
phages, monocytes, fibroblasts, mesothelial cells, mesan-
gial cells, endothelial cells, as well as numerous neoplastic 
cells.
To exert biological activity, IL-6 requires binding to the 
IL-6R receptor (gp-80, glycoprotein-80) on the cell surface 
(mIL-6R, IL-6 membrane receptor) or in a soluble form (sIL- 
-6R, soluble IL-6 receptor). Binding with the receptor results 
in a conformational change of glycoprotein-130 (gp-130), 
followed by autophosphorylation of gp-130-associated JAK 
kinase (Janus activated kinase), and phosphorylation of 
gp-130. The sequence of events leads to the activation 
of two signal pathways: STAT-3 (signal transducer and 
activator of transcription 3) and MAPK. In the nucleus, 
STAT-3 binds to the promoters of the acute phase inflam-
matory response genes. IL-6 plays an important role in in-
flammation and regulation of the immune response.
Specifically, it: 1) stimulates B cells and plasma cells to 
produce immunoglobulins (polyclonal hypergammaglobu-
linemia); 2) together with IL-1, it activates T cells and anti-
gen-presenting macrophages during acute phase reaction; 
3) it participates in switching between the innate response 
(infiltration of neutrophils) and the specific response (in-
filtration of monocytes and lymphocytes); 4) it stimulates 
angiogenesis by upregulation of VEGF; and 5) it is involved 
in the production of acute phase proteins in the liver, in-
cluding haptoglobin, C-reactive protein (CRP), and hepcidin 
(decreased production of albumin, iron blocking for haemo-
globin) [5, 20]. IL-6 presumably plays an important role in 
the development of autoimmune disorders associated with 
CD (haemolytic anaemia and immune thrombocytopenia) 
by stimulating CD5+ B cells to produce autoantibodies. An 
excess of IL-6 disrupts the ratio between Th17 cells (excess 
of pro-inflammatory helper cells) and Treg (regulatory lym-
phocytes protecting from autoimmunity). The other key 
cytokines include IL-1, which plays a more significant role 
in the pro-inflammatory cascade of events than does IL-6. 
A frequently observed elevated VEGF level is responsible for 
increased angiogenesis and permeability of blood vessels.
In cases of concomitant POEMS and MCD (POEMS-
-MCD), excessive VEGF secretion may stimulate the pro-
duction of IL-6. In other cases (POEMS-like symptoms with-
out the presence of monoclonal plasmocytes), the inverse 
mechanism is proposed, with stimulation of VEGF secre-
tion by IL-6 [5, 14]. Recently, excessive activation of CD8+ 
T cells, VEGF-A and the PI3K/AKT/mTOR pathway has been 
confirmed in patients resistant to IL-6 blockade [19].
Diagnosis, pathomorphology
HP image of the enlarged lymph nodes is characteristic, 
but not specific to CD. Similar or even identical lesions are 
described in virtually all enlarged lymph nodes in patients 
with RA, in approximately 30% of patients with SLE, and in 
many other inflammatory and infectious diseases [16]. The 
ultimate diagnosis requires a comparison between the HP 
images and clinical symptoms, and the results of laboratory 
workups with the simultaneous exclusion of inflammation, 
autoimmune, and neoplastic diseases.
In 2017, the panel of CDCN experts released the first 
unified diagnostic criteria of iMCD. According to this, two 
major criteria must be met: typical HP image, and lymph 
node enlargement ≥1 cm in the short axis in at least two 
locations. These two major criteria should be accompanied 
by at least two out of 11 minor criteria (including at least 
one laboratory criterion). At the same time, it is necessary 
to exclude all syndromes and diseases overlapping with 
iMCD (Table I) [6]. There are four HP variants of CD: 1) hya-
line vascular (HV), characterised by sclerosis of blood ves-
sels in atrophic germinal centre, concentrically surrounded 
by small lymphocytes in enlarged mantle zone; 2) plasma 
cell (PC) with expanded germinal centres and proliferating 
plasma cells; and 3) mixed variant (MV) with HV and PC 
features and plasmablastic cell (PB) variant present only 
in HIV-associated MCD [6].
Clinical presentation
The idiopathic form of MCD most often affects men aged 
40–60 (median 50 years). The plasma cell variant is 
observed in 40% of patients, mixed in 40%, and the least 
common (<20%) is the hyaline vascular variant (character-
istic for UCD). The most common symptoms of a relatively 
mild form of iMCD include progressive malaise, fatigue, 
exercise intolerance, general symptoms (fever, night 
sweats, weight loss), usually moderate lymphadenopa-
thy (sometimes spontaneous regression of lesions), and 
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hepatosplenomegaly. Approximately 10–20% of patients 
experience more severe symptoms of systemic inflamma-
tion, and in addition to ‘fatigue syndrome’, also vascular 
leakage syndrome with clinically significant peripheral 
oedema, fluid accumulation in body cavities (pleura, perito-
neum, or pericardium) or symptoms of organ failure (most 
commonly kidneys and lungs) [11, 16, 21, 22]. In rare 
cases, the symptoms can be life-threatening.
The diagnostic criteria for severe iMCD have recently 
been defined by the CDCN. These include organ damage, 
most commonly kidney disease (eGFR <30 mL/min, cre-
atinine >3.0 mg/dL), respiratory failure (interstitial lung in-
flammation or fibrosis), increased fluid retention (oedema, 
ascites, pleural or pericardial effusion), severe anaemia 
(haemoglobin ≤8 g/dL) and significant deterioration in 
performance status [Eastern Cooperative Oncology Group 
(ECOG) ≥2]. A diagnosis requires at least two of these symp-
toms (Table II). Usually in these cases significant laboratory 
abnormalities are present, such as high CRP level (≥100 g/ 
/dL), hypoalbuminaemia (≤2.0 g/dL), and thrombocytope-
nia (≤100 g/L) [23].
TAFRO syndrome is a unique form of iMCD. It was first 
described in 2010 in Japan as a syndrome consisting of 
thrombocytopenia, ascites, reticulin bone marrow fibrosis, 
renal dysfunction, and organomegaly (TAFRO = thrombo-
cytopenia, ascites, fibrosis, renal, organomegaly). It is pre-
sumed that the spectrum of cytokines involved in the de-
velopment of TAFRO syndrome may differ slightly from the 
Table I. Consensus diagnostic criteria for idiopathic multicentric Castleman disease (iMCD) according to Castleman Disease Collaborative 
Network (CDCN) (2017) [6]
MAJOR CRITERIA (both must be met)
1. Histopathological confirmation of lesions typical for CD, based on lymph node examination
2. Lymphadenopathy ≥1 cm in the short axis, in at least ≥2 areas
MINOR CRITERIA (at least two of these 11 must be met, including at least one laboratory criterion)
Laboratory criteria
1. CRP >10 mg/L or ESR >15 mm/h
2. Anaemia, Hb <12.5 g/dL for men and <11.5 g/dL for women
3. Thrombocytopenia, PLT <150 G/L or thrombocytosis, PLT >400 G/L
4. Hypoalbuminemia (albumin <3.5 g/dL)
5. Renal failure (eGFR <60 mL/min/1.73 m2) or proteinuria (total protein >150 mg/24 h or >10 mg/100 mL)
6. Polyclonal hypergammaglobulinemia (IgG >1,700 mg/dL)
Clinical criteria
7. General symptoms: night sweats, fever >38°, weight loss, fatigue (≥2 CTCAE)
8. Enlargement of spleen and/or liver
9. Fluid retention: oedema, ascites, pleural/pericardial effusions
10. Eruptive cherry haemangiomatosis or follicular lesions: violaceous papules
11. Lymphocytic interstitial pneumonia
EXCLUSION CRITERIA (it is necessary to exclude all entities resembling iMCD)
1. Infectious diseases
HHV-8 (LANA-1 negative in IHC, PCR negative)
EBV-lymphoproliferative disease
CMV, toxoplasmosis, HIV, active tuberculosis
2. Autoimmunological diseases (diagnosis based on applicable criteria for a given disease; presence of autoantibodies is not a crite-
rion that excludes iMCD)
SLE, RA, Still’s disease, juvenile idiopathic arthritis, autoimmune lymphoproliferative syndrome
3. Neoplastic diseases
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma , multiple myeloma, isolated plasmacytoma, follicular dendritic cell sarcoma (FDC 
sarcoma), POEMS syndrome
CD — Castleman disease; CRP — C-reactive protein; ESR — erythrocyte sedimentation rate; Hb — haemoglobin; PLT — platelets; eGFR — estimated glomerular filtration rate; IgG — immunoglobulin G; CTCAE — Com-
mon Terminology Criteria of Adverse Events; HHV-8 — human herpesvirus 8; LANA-1 — latency-associated nuclear antigen; IHC — immunohistochemistry; PCR — polymerase chain reaction; EBV — Ebstein-Bárr 
virus; CMV — cytomegalovirus; HIV — human immunodeficiency virus; SLE — systemic lupus erythematosus; RA — rheumatoid arthritis; FDC — follicular dendritic cell; POEMS — polyneuropathy, organomegaly, 
endocrinopathy, monoclonal protein, skin lesions
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classical cytokines associated with iMCD-NOS. This explains 
the thrombocytosis and hypergammaglobulinemia typical for 
the diagnosis of iMCD-NOS, and the thrombocytopenia and 
normal or only slightly elevated levels of immunoglobulins 
observed in TAFRO syndrome. The latter is usually associated 
with a severe course of disease and a poor prognosis [12].
CD might be associated with paraneoplastic pemphigus 
(PNP), a very rare symptom often associated with UCD, and 
symptoms resembling POEMS syndrome, including poly-
neuropathy, present in approximately 2% of patients [21]. 
Typical laboratory abnormalities include normocytic anae-
mia, thrombocytosis or TAFRO-associated thrombocytope-
nia, high CRP and erythrocyte sedimentation rate (ESR), 
elevated fibrinogen, polyclonal gammopathy, decreased 
albumin level, as well as increased IL-6 and VEGF. Bone 
marrow examination often shows an increased percentage 
of polyclonal plasmacytes. In the peripheral blood, auto-
antibodies against erythrocytes and platelets, as well as 
antinuclear antibodies, are often present [6].
Treatment of idiopathic multiple Castleman 
disease based on guidelines of CDCN
The idiopathic form of MCD may be asymptomatic, with 
mild or moderate systemic symptoms, or immediately 
life-threatening ‘cytokine storm’ syndrome leading to multi-
organ failure. The therapeutic approach to iMCD varies due 
to the vast array of symptoms observed in the course of 
the disease. The first attempt to systematise the diagnostic 
and therapeutic recommendations was recently made by 
the CDCN expert panel. In 2016–2018, based on a few 
published studies and case reports (344 patients) and 
analysis of the treatment regimens used (479 regimens), 
the CDCN developed a consensus on three key issues for 
iMCD. The diagnosis criteria for the severe form of iMCD 
were defined (Table II), treatment algorithms were proposed 
(Table III), and treatment response evaluation criteria were 
developed (Table IV) [23].
Treatment of mild iMCD
Patients who do not meet the criteria of severe iMCD (Ta-
ble II), without obvious organ dysfunction, in relatively good 
general condition, with moderate severity of IL-6-dependent 
inflammatory symptoms (fatigue, anaemia, impaired 
exercise tolerance, peripheral oedema) may require treat-
ment due to their deteriorating quality of life, expressed 
not only by the disturbance in performing daily activities, 
but also by limitations in their professional life. Clinically 
significant lymphadenopathy is a rare indication for treat-
ment initiation. Based on the results of a phase II study 
(the only randomised, double-blind, placebo-controlled 
study), the CDCN recommends (category 1) first-line treat-
ment with an anti-interleukin 6 (anti-IL-6) monoclonal 
antibody, siltuximab (11 mg/kg i.v. every three weeks) 
[23]. The safety of the drug was confirmed by the results 
of long-term observation in a previous phase I/II study, in 
which the median duration of treatment was 5.1 (range 
3.4–7.2) years, with a median of 81 cycles administered 
(range 49–129). In this study, as many as 74% of patients 
Table II. Diagnostic criteria of severe idiopathic multicentric Castle-
man disease (iMCD) according to Castleman Disease Collaborative 
Network (CDCN) (2018) [23]
Severe iMCD symptoms
1. ECOG ≥2
2. Grade IV renal failure (eGFR <30 mL/min, creatinine 
>3.0 mg/dL)
3. Ascites and/or oedema and/or pleural/pericardial effu-
sion 
4. Haemoglobin ≤8.0 g/dL
5. Respiratory failure, shortness of breath,  
symptoms of interstitial lung inflammation or fibrosis
The diagnosis of severe iMCD requires at least two of these five symptoms; ECOG — Eastern Co-
operative Oncology Group/ECOG performance status; eGFR — estimated glomerular filtration rate
Table III. Treatment recommendations for idiopathic multicentric 
Castleman disease (iMCD) according to Castleman Disease Col-










± HD methyprednisolone 
± cyclosporine**
Second-line therapy
Rituximab ± prednisone 
± immunomodulator 
(thalidomide)










*According to CDCN recommendations, first-line rituximab is recommended when anti-IL-6/IL-6R 
antibodies are unavailable, or when short-term anti-CD20 therapy is considered as an alternative to 
long-term anti-IL6 therapy; **combination of tocilizumab, HD-steroids, cyclosporine recommended 
by Japanese research group in iMCD-TAFRO therapy; ***TCP regimen [31] with an immunomodula-
tory drug in second-line of treatment or in first-line when anti IL-6/IL-6R are unavailable; NOS — not 
otherwise specified; TAFRO — thrombocytopenia, ascites, fibrosis, renal, organomegaly; IL-1 — inter-
leukin 1; HD — high dose; CVP — cyclophosphamide, vincristine, prednisone; CHOP — cyclophospha-
mide, adriamycin, vincristine, prednisone
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stayed on treatment for at least four years [24, 25]. The 
phase II study included 79 patients (iMCD) randomised to 
siltuximab or a placebo arm. In the siltuximab group, 34% 
nodal regression responses (complete or partial remission 
maintained for at least 18 weeks) were achieved, but no 
remission was observed in the placebo group. Benefit from 
the administration of siltuximab, defined as a significant 
improvement or relief of symptoms related to the disease, 
was observed in 60% of patients [26].
Data analysis and clinical experience indicate that the 
greatest benefit from the administration of anti-IL-6 treat-
ment is achieved in patients with severe cytokine-depen-
dent symptoms, defined as the presence of laboratory ab-
normalities (high CRP, ESR, fibrinogen, hypergammaglob-
ulinemia, significant anaemia, hypoalbuminemia). Final 
analysis for the predictive model of response to siltuximab 
identified four important parameters: elevated fibrinogen 
levels, CRP, hypergammaglobulinemia, and decreased 
haemoglobin levels. The level of IL-6 alone did not influ-
ence the response [27]. The expected effect of siltuximab 
on nodal regression requires time, as this drug has no di-
rect cytotoxic effect. In the phase II study, mean time to 
obtain overall response rate (ORR), defined as CR or PR, 
was five months [26]. It is recommended that in the early 
stages of treatment, biochemical parameter monitoring 
(CRP, ESR, albumin) and the improvement or resolution 
of disease-related symptoms should be used to evaluate 
treatment response. Nodal remission evaluation (using 
diagnostic imaging) should not be performed earlier than 
three months after treatment initiation [14, 23]. Patients 
who benefit from siltuximab treatment should continue 
the treatment, because there is a risk of relapse after 
treatment cessation. In a small group of patients receiv-
ing the drug for a long time, the intervals between doses 
were safely extended from three to six weeks, but the final 
effect of such a procedure requires longer observation. 
Many years of follow-up of patients receiving siltuximab 
did not reveal any significant treatment-related complica-
tions. The most frequently observed side effects include 
lipid disorders (hypertriglyceridemia, hypercholesterolae-
mia), a slight decrease in platelet count, and itching [25]. 
Based on the results of the phase II study, siltuximab has 
been approved for the treatment of iMCD in the United 
States and the European Union.
When siltuximab is unavailable, anti-interleukin 6 re-
ceptor monoclonal antibody (anti-IL-6R), tocilizumab (8 mg/ 
/kg b.w. i.v. every two weeks), is recommended by the 
CDCN as an alternative first-line treatment (category 2A). 
This drug has similar safety and efficacy profiles to siltux-
imab, but the evidence for its effectiveness is not supported 
by a randomised controlled trial. In a small, prospective, 
single-arm study (35 patients with iMCD), 86% of patients 
who continued treatment for at least five years benefited 
from tocilizumab. However, the effectiveness of the drug 
is determined here only by the percentage of patients who 
continued treatment (86%), and objective response criteria 
were not shown [28]. The drug has been approved for the 
treatment of iMCD in Japan. It is not recommended to ini-
tiate anti-IL-6 (siltuximab) or anti-IL-6R (tocilizumab) ther-
apy solely based on IL-6 levels. In the phase II study with 
siltuximab, several cases of patients with low or normal 
IL-6 levels who responded to treatment, as well as cases 
of patients with high levels of IL-6 without response to the 
antibody, were observed [26]. IL-6 concentration was not 
considered a criterion of response to the treatment be-
cause both siltuximab and tocilizumab can cause false el-
evations in IL-6 levels even up to 24 months after the final 
dose of the drug [14, 23, 29].
Depending on the clinical situation, anti-IL-6 therapy 
can be administered in combination with corticosteroids. 
Prednisone (1 mg/k b.w. for 4–8 weeks) should be con-
sidered with a gradual dose reduction (category 2B). It is 
possible to use higher doses of steroids depending on the 
clinical need. It is not recommended to administer corti-
costeroids in monotherapy because, despite their initially 
high effectiveness (46% ORR), extended treatment is asso-
ciated with a high rate of progression or requires a change 
of therapy due to side effects (54% failures) [23].
Table IV. Response criteria according to Castleman Disease Collaborative Network (CDCN) (2018) [23]
Complete response 
(1 +2 +3)
1. Laboratory workup: Hb, CRP 
albumins, eGFR 
2. Assessment of nodal lesions 
according to Cheson
3. Evaluation of systemic symptoms: 
fatigue, anorexia, fever, body weight*
CR Normal CR Complete resolution of symptoms
PR >50% improvement from base-
line applies to all parameters
PR Improvement in all symptoms 
(but not complete resolution)
SD Improvement <50% or deterio-
ration <25% of all parameters 
Does not meet CR, PR or PD 
criteria
Improvement in at least one symptom 
(but not all)
PD Deterioration of >25% of one 
parameter
PD Worsening of at least one symptom as-
sessed at least twice four weeks apart
*Symptom Severity Score assessed by Common Terminology Criteria of Adverse Events (CTCAE) version 4, improvement in fatigue, appetite and fever symptoms is ≥1 grade CTC reduction from baseline, 
weight gain ≥5% increase to baseline values; Hb — haemoglobin; CRP — C-reactive protein; eGFR — estimated glomerular filtration rate; CR — complete remission; PR — partial remission; SD — stable disease; 
PD — progressive disease
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If anti-IL6/anti-IL6R antibodies are unavailable, the 
alternative first-line treatment should consist of anti-
CD20 monoclonal antibody, rituximab (375 mg/m2 i.v., 
4–8 doses), most often in combination with steroids (cat-
egory 2B). Rituximab can be administered initially in weekly 
infusions (four doses) or at 2–3 weekly intervals (6–8 dos-
es) until the major systemic symptoms (e.g. general symp-
toms, fever, malaise) resolve. According to the CDCN rec-
ommendations, rituximab is proposed as the first-line drug 
for patients who are considering the possibility of short-
-term therapy (4–8 cycles) as an alternative to long-term 
anti-IL-6 therapy [23]. Long-term maintenance treatment 
with rituximab is not recommended.
There is no conclusive evidence for the efficacy of 
rituximab in patients with idiopathic MCD, as the evalua-
tion of its efficacy is mainly based on the experience with 
HIV+/HHV-8+ MCD. The results of a retrospective analysis 
comparing the efficacy of siltuximab to that of rituximab 
for iMCD patients indicate that the anti-IL6 (siltuximab)- 
-terated group had a significantly higher CR rate (p =0.034) 
and progression-free survival (PFS). It is worth noting that 
in the siltuximab group, approximately 75% of objective 
responses (ORR), defined as regression of nodal lesions, 
were achieved. This is a much higher percentage compared 
to the registration phase II study (34% ORR) [22]. The dis-
crepancy in the obtained results is explained by the fact 
that the patients enrolled to the phase II study had less 
severe systemic symptoms, which made the placebo arm 
possible, while patients from the retrospective analysis 
constituted the ‘real life’ population presenting a typical 
broad spectrum of symptoms. This observation seems to 
confirm that anti-IL-6 efficacy is directly correlated with the 
severity of inflammatory symptoms.
First-line anti-IL-6/ anti-IL-6R treatment failure is ob-
served in approximately 40–50% of patients. In these 
cases, it is recommended to use immunomodulatory or 
immunosuppressive drugs, possibly in combination with 
steroids and rituximab (category 2B). The most important 
immunomodulatory drug, thalidomide, is effective in mono-
therapy as well as in combination with rituximab. It lowers 
IL-6 expression and shows anti-angiogenic activity by low-
ering VEGF [23, 30]. In 2019, the results of a prospective 
phase II study were published. The study aimed to evalu-
ate the effectiveness of the TCP regimen based on the use 
of oral immunochemotherapy (TCP: thalidomide 100 mg 
daily for two years, oral cyclophosphamide 300 mg/m2 on 
days 1, 8, 15, and 22 in a 28-day cycle for one year, pred-
nisone 1 mg/kg b.w. on days 1, 2, 8, 9, 15, 16, 22, 23 in 
a 28-day cycle for one year). A high percentage of objective 
responses (48% ORR) was achieved in the group of previ-
ously untreated patients, with good treatment tolerance. 
Based on these results, TCD regimen can be considered 
as a first-line treatment, especially in countries where sil-
tuximab or tocilizumab are unavailable [31].
The recommendations for the third and subsequent 
lines of treatment are not strictly defined. According to the 
CDCN, if iMCD does not meet the severe form criteria, clas-
sic chemotherapy regimens should be avoided [23]. It is rec-
ommended to use other immunomodulatory or immunosup-
pressive drugs, because their effectiveness is comparable 
to classic chemotherapy (ORR 69%), but with significantly 
lower toxicity. The use of lenalidomide, bortezomib, cyclo-
sporin A, or an IL-1β receptor antagonist anakinra (supe-
rior control of IL-1 over IL-6) should be considered [14, 22, 
23, 32–34]. The efficacy of the mTOR pathway antagonist 
sirolimus has also been reported. A study is currently un-
derway to assess the efficacy of sirolimus in patients af-
ter treatment failure with anti-IL6 (NCT03933904) [19].
Treatment of severe iMCD
It is estimated that the severe form of iMCD accounts for 
about 10–20% of all CD cases. Clinically significant organ 
dysfunction (renal failure, massive oedema and exudates, 
respiratory failure, poor general condition) can be life-
threatening. This group of patients requires urgent use of 
high doses of steroids. It is recommended (category 1) to 
administer methylprednisolone at a dose of 500 mg/day 
simultaneously with siltuximab, which in this situation may 
be administered once a week for the first month of intensive 
care (11 mg/kg b.w. at days 1, 8, 15, 22). The patients 
who benefit from the treatment should continue siltuximab 
therapy in the standard regimen (every three weeks). At the 
same time, it is recommended to gradually reduce the doses 
of steroids until their complete discontinuation as soon as 
possible. An alternative option is to use tocilizumab (cat-
egory 2A). Due to the high risk of mortality in severe iMCD, 
it should be remembered that not all patients will respond 
to the treatment quickly. Some will not respond to the com-
bination of anti-IL-6 with steroids. Careful daily monitoring of 
the patient’s condition and laboratory parameters to evalu-
ate the response is recommended. If the general condition 
deteriorates, or no improvement is observed after a week 
of siltuximab administration, conventional cytostatics in 
multidrug regimens typically used to treat non-Hodgkin’s 
lymphoma, multiple myeloma or haemophagocytic lympho-
histiocytosis (HLH) should be administered [23].
The most commonly used regimens include: CVP ± R 
(cyclophosphamide, vincristine, prednisone ± rituximab), 
CHOP ± R (cyclophosphamide, adriamycin, vincristine, 
prednisone/dexamethasone ± rituximab), VDT-ACE-R (bort-
ezomib, dexamethasone, thalidomide, adriamycin, cyclo-
phosphamide, etoposide, rituximab), and HLH-scheme 
(etoposide, prednisone/dexamethasone, cyclosporine). 
Experience with the administration of these regimens is 
based on small groups of patients, and the evaluation of 
their effectiveness comes from retrospective analyses and 
case reports [23, 35]. Attempts to perform autologous or 
allogenic transplantation are casuistic and, according to 
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the recommendations of CDCN experts, should be consid-
ered only as a last resort therapy (with the exception of 
POEMS-MCD with bone lesions as an indication for autolo-
gous transplantation) [14, 23].
Severe iMCD often meets the criteria for TAFRO syn-
drome. In such cases, the CDCN recommends the same 
procedure as for iMCD-NOS. It seems that cyclosporine 
may play an important role in the therapy of TAFRO, espe-
cially in cases of recurrent thrombocytopenia and ascites. 
The Japanese research group recommends the use of to-
cilizumab in combination with cyclosporine and high doses 
of steroids in patients with TAFRO syndrome [36]. The ef-
fectiveness of other immunosuppressants, including calci-
neurin inhibitor (tacrolimus) and mTOR inhibitor (sirolimus), 
has also been described [37, 38].
Treatment response evaluation
The criteria for evaluation of treatment response were 
standardised by the CDCN in 2017 (Table IV). Comprehen-
sive evaluation of treatment response includes: 1) labora-
tory evaluation of inflammatory markers including four 
parameters: haemoglobin (Hb), CRP, albumin, and eGFR; 
2) regression of nodal lesions according to modified Che-
son criteria [39]; and 3) assessment of clinical symptoms 
(fatigue, eating disorders, fever, body weight) according to 
the National Cancer Institute Common Terminology Criteria 
of Adverse Events scale [version 4 of the National Cancer 
Institute — Common Toxicity Criteria (NCI–CTC) of adverse 
events (AE)]. CR requires normalisation of all biochemical 
parameters, PR is defined as improvement ranging from 
50% to 99% of baseline, while stable disease (SD) is defined 
as an improvement of less than 50% of baseline or deterio-
ration of any of the parameters <25%. Progressive disease 
(PD) is defined as a deterioration of any of the parameters 
by >25% of baseline. Relief of all disease-related symptoms 
or improvement in their severity (but not complete resolu-
tion) as assessed by the Common Terminology Criteria of 
Adverse Events (CTCAE) scale indicates CR or PR in the as-
sessment of systemic symptoms. In this case, progression 
means the deterioration of one of the symptoms observed 
on at least two consecutive visits, four weeks apart [23].
CDCN Project, NCT02817997
As part of the CDCN-supported project (NCT02817997), 
each patient can register their medical history at http:// 
//www.cdcn.org/accelerate. The purpose of the registry 
is to obtain demographic, clinical and laboratory data for 
further research into understanding this rare disease [14].
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